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Abstract
In 2009, the United States approved quadrivalent HPV vaccine for males 9–26 years old, but data
on vaccine uptake are lacking. We determined HPV vaccine uptake among adolescent males, as
well as stage of adoption and vaccine acceptability to parents and their sons. A national sample of
parents of adolescent males ages 11–17 years (n=547) and their sons (n=421) completed online
surveys during August and September 2010. Analyses used multivariate linear regression. Few
sons (2%) had received any doses of HPV vaccine, and most parents and sons were unaware the
vaccine can be given to males. Parents with unvaccinated sons were moderately willing to get their
sons free HPV vaccine (mean=3.37, SD=1.21, possible range 1–5). Parents were more willing to
get their sons vaccinated if they perceived higher levels of HPV vaccine effectiveness (β=0.20) or
if they anticipated higher regret about their sons not getting vaccinated and later developing an
HPV infection (β=0.32). Vaccine acceptability was also modest among unvaccinated sons
(mean=2.98, SD=1.13, possible range 1–5). Sons were more willing to get vaccinated if they
perceived higher peer acceptance of HPV vaccine (β=0.39) or anticipated higher regret about not
getting vaccinated and later developing an HPV infection (β=0.22). HPV vaccine uptake was
nearly nonexistent a year after permissive national recommendations were first issued for males.
Vaccine acceptability was moderate among both parents and sons. Efforts to increase vaccine
uptake among adolescent males should consider the important role of peer acceptance and
anticipated regret.
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Human papillomavirus (HPV) infection is the most common sexually transmitted infection
(STI) in the United States (U.S.) [1]. Prevalence estimates of infection among asymptomatic
males are typically over 20% and range as high as 73% [2]. Although infection is generally
less common among adolescent and young adult males compared to older males [3–5],
infection often occurs soon after sexual debut or the introduction of new sexual partners [6].
HPV infections have the potential to cause various adverse health outcomes in males,
including genital warts [7,8] and some types of cancer (anal, penile, and oral cancers) [9].
HPV concordance levels are high among sexual partners [10], so infected males also put
their female partners at increased risk of cervical disease [11,12].
The U.S. Food and Drug Administration (FDA) approved a quadrivalent HPV vaccine
against HPV types 6, 11, 16, and 18 for use in males ages 9–26 in October 2009 [13]. Soon
after, the Advisory Committee on Immunization Practices (ACIP) provided a permissive
recommendation, allowing for the administration of the 3-dose vaccine series to males ages
9–26 but not making it part of their routine vaccination schedule [13]. The ACIP also
recommended HPV vaccine be covered by the Vaccines for Children (VFC) program for
eligible males ages 18 or younger [14]. Coverage of the vaccine for males is less clear for
private health insurance plans, though not all plans currently provide coverage [15]. The
FDA has approved HPV vaccine for genital warts and anal cancer prevention in males
[16,17], while the ACIP recommends the vaccine to reduce the likelihood of genital warts in
males [13] and is considering its potential to prevent cancer in males. In addition to these
individual health benefits, vaccinating males ages 9–26 against HPV also has considerable
public health and economic benefits [18].
Studies conducted in the U.S. before HPV vaccine licensure for males found relatively high
levels of parental acceptability of the vaccine for their adolescent sons [19]. Our own
research conducted soon after vaccine licensure also showed many parents were willing to
get their adolescent sons free HPV vaccine [20]. No studies we are aware of, however, have
assessed actual HPV vaccine uptake among adolescent males in the U.S. Furthermore,
although research has examined vaccine acceptability to male college students and other
young adult males [19,21–23], we are not aware of data on acceptability of HPV vaccine to
younger adolescent males. Examining vaccine acceptability among this age group is
important because HPV vaccine is most effective if given prior to HPV exposure through
sexual contact [13], many adolescents are involved in deciding whether they get vaccinated
[24], and younger adolescents are the target group for adolescent vaccination platforms [25].
To address these gaps in the existing literature, we collected dyadic data on HPV vaccine
uptake and acceptability from parents and their adolescent sons.
2. Materials and Methods
2.1. Study Design
The HPV Immunization in Sons (HIS) study surveyed parents and their 11–17 year old sons
to examine their attitudes and beliefs about HPV vaccination for males. Parents were
existing members of a national panel of U.S. households maintained by a survey company
[26]. The national panel is a probability-based sample of US households constructed through
a dual frame approach (list-assisted, random-digit dialing supplemented by address-based
sampling). The survey company provides a laptop and free internet access to non-Internet
households so panel members can complete multiple online surveys each month. Panel
members in households with existing computer and internet access accumulate points for
completing surveys that can later be redeemed for small cash payments.
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We asked participating parents to also allow their sons to participate in our study. For
parents with multiple sons ages 11–17, we asked them to answer questions about their son
who had the most recent birthday. This same son became eligible for possible participation
in the son survey. Parents provided consent for their own participation and their sons’
participation prior to the start of the parent surveys. For those parents who provided consent
for their sons, we then obtained sons’ assent prior to the start of the son surveys.
The survey company invited 1195 parents by email to participate, of whom 752 responded
to their invitation. Among those who responded, 73% (n=547) were eligible and completed
the parent survey; 56% (n=421) had sons who also completed a survey. Sons who did not
complete surveys lacked either parents’ consent (n=119) or sons’ assent (n=7). Participants
completed surveys online in August and September 2010. Parents received their standard
incentives for participating and sons received 5,000 points ($5 equivalent). The Institutional
Review Board at the University of North Carolina approved the study.
2.2. Measures
The parent and son surveys are available online at http://www.unc.edu/~ntbrewer/hpv.htm.
We developed survey items based on our previous HPV vaccine research among parents,
females, and healthcare providers [20,27–29]. We cognitively tested survey items with 6
parent-son dyads, refined the items, and then pretested the survey with 31 parents and 23
adolescent sons. Since our past research indicated that few parents knew HPV vaccine was
available for males [20], we provided parents and sons with informative statements about
HPV and HPV vaccine throughout the survey. Statements described what HPV is and the
diseases it can cause, that HPV vaccine was recently approved for males ages 9–26, the
number of doses in the vaccine series, and the potential health benefits the vaccine has for
males.
We asked parents and sons if sons had received any doses of HPV vaccine (i.e., vaccine
initiation). For parents who indicated vaccine initiation, we asked the main reason why they
got their sons the vaccine and how much the first dose of HPV vaccine cost. For parents and
sons who did not indicate HPV vaccine initiation, we classified their stage of adoption of
HPV vaccination for males [30,31]: (a) unaware: unaware HPV vaccine could given to
males; (b) unengaged: aware the vaccine could given to males but had not thought about
getting their sons (parent survey) or themselves (son survey) vaccinated; (c): undecided:
thought about getting their sons (parent survey) or themselves (son survey) vaccinated but
undecided about vaccination in the next year; (d) decided not to act: does not want to
vaccinate in the next year; or (e) decided to act: wants to vaccinate in the next year.
The parent survey assessed willingness to get their sons HPV vaccine if it were free using a
5-point scale with responses of “definitely not willing”, “probably not willing”, “not sure”,
“probably willing”, and “definitely willing” (possible range=1–5). We measured parents’
worry about their sons getting HPV-related disease (possible range=1–4), likelihood of their
sons getting HPV-related disease (possible range=1–4), and perceived effectiveness of HPV
vaccine against genital warts (possible range=1–4). Parents indicated how comfortable they
were talking with their sons about new vaccines that could prevent cancer or an STI (2
items, α=0.68, possible range=1–5), how much they had talked with their sons about HPV
vaccine (possible range=1–4), whether they thought their sons’ insurance covered HPV
vaccine, if their sons’ doctors ever said their sons should get HPV vaccine, and if they had
any daughters ages 9–26 who had received HPV vaccine.
Using items based on the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS)
[32], the parent survey measured perceived potential harms of HPV vaccine (5 items,
α=0.57, possible range=1–5), perceived barriers to getting sons HPV vaccine (2 items,
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α=0.62, possible range=1–3), and uncertainty about HPV vaccine (3 items, α=0.55, possible
range=1–5). We assessed parents’ anticipated regret if their sons received HPV vaccine and
fainted (possible range=1–4) and if their sons did not get vaccinated and later developed an
HPV infection (possible range=1–4).
The son survey assessed their willingness to get HPV vaccine using a 5-point scale with
responses of “definitely not willing”, “probably not willing”, “not sure”, “probably willing”,
and “definitely willing” (possible range=1–5). We asked sons 5 HPV knowledge items and
classified them as: (a) unaware of HPV (had never heard of HPV before the survey); (b)
aware with low HPV knowledge (answered 2 or fewer knowledge items correctly); or (c)
aware with high knowledge (answered 3 or more knowledge items correctly). We measured
sons’ perceived knowledge about HPV vaccine (possible range=1–4), peer acceptance of
HPV vaccine (4 items, α =0.69, possible range=1–5), and potential embarrassment if they
got vaccinated (2 items, α=0.90, possible range=1-5). Using corresponding items and
response scales to those on the parent survey, the son survey assessed perceived likelihood
of getting HPV-related disease (possible range=1-4), comfort in talking with their parents
about new vaccines (2 items, α=0.71, possible range=1–5), how much they had talked with
their parents about HPV vaccine (possible range=1–4), anticipated regret if they got HPV
vaccine and fainted (possible range=1–4), and anticipated regret if they did not get
vaccinated and later developed an HPV infection (possible range=1–4).
We collected information on various demographic characteristics (Table 1). We defined
“urban” as living in a metropolitan statistical area (MSA) and “rural” as living outside of an
MSA [33]. The survey measured parents’ political affiliation with responses ranging from
“very conservative” to “very liberal” (possible range=1–5) and importance of religion with
responses ranging from “not at all important” to “extremely important” (possible range=1–
5). We assessed whether parents were born-again Christians with the item, “Do you consider
yourself a born-again or evangelical Christian?” [34].
2.3. Data Analysis
We used descriptive statistics to examine HPV vaccine uptake and stage of adoption for
parents and sons. We then used linear regression to identify correlates of parents’
willingness to get their sons free HPV vaccine and sons’ willingness to get vaccinated.
Statistically significant bivariate correlates (p<0.05) were entered into a multivariate model
for each outcome. We report standardized regression coefficients (β) from these linear
regressions. We calculated Pearson’s correlation coefficient to determine the correlation
between parents’ and sons’ willingness. Analyses of unweighted data used SPSS version




Most parents were younger than 45 years of age (61%), non-Hispanic white (67%), and
married or living with a partner (82%) (Table 1). About half of parents were female (54%),
had at least some college education (56%), and reported a household income of at least
$60,000 (49%). The sample included parents from all four geographic regions of the U.S.
and primarily from urban areas (83%). Most sons who completed a survey were non-
Hispanic white (61%) and had seen their healthcare provider in the last year (77%). About
30% of sons were ages 11–12, with 38% ages 13–15, and 32% ages 16–17. Sons who
completed surveys had similar characteristics to non-completers, as did their parents (all
p>0.05).
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3.2. Vaccine Uptake and Stage of Adoption
Only 2% (12/547) of sons had received any doses of HPV vaccine, of which only 2 (<1%)
had received all 3 doses. Half of parents with vaccinated sons indicated their main reason for
vaccinating was because of a doctor’s recommendation (n=6), with fewer reporting genital
warts prevention (n=2) or cancer prevention (n=1) as the main reason. All but 1 parent
indicated that their sons’ health insurance covered all costs for the first dose of HPV
vaccine.
Among parents of unvaccinated sons (n=535), most were in the early stages of adoption,
with 80% unaware that HPV vaccine can be given to males and 13% unengaged. Few
parents were in the later stages of adoption: 2% were undecided about vaccination in the
next year, 1% did not want to vaccinate their sons in the next year, and 4% wanted to
vaccinate in the next year. Similar to parents, most unvaccinated sons who completed a
survey (n=412) were unaware (90%) or unengaged (6%). Few sons were undecided about
vaccination in the next year (1%), did not want to get vaccinated in the next year (1%), or
wanted to get vaccinated in the next year (2%).
3.3. Parents’ Willingness to Get Sons HPV Vaccine
Parents with unvaccinated sons reported fairly low levels of worry and perceived likelihood
of their sons getting HPV-related disease (Table 2). Although parents reported high levels of
comfort in talking with their sons about new vaccines, they had talked little with their sons
about HPV vaccine. Only 21% of parents thought their sons’ health insurance covered HPV
vaccine (69% did not know), and only 3% reported their sons’ doctors said their sons should
get HPV vaccine. Parents perceived moderate levels of HPV vaccine effectiveness, potential
harms of the vaccine, and barriers to getting their sons vaccinated. Most parents indicated
fairly high levels of uncertainty about the vaccine, anticipated regret if their sons got
vaccinated and fainted, and anticipated regret if their sons didn’t get vaccinated and later got
an HPV infection.
Parents with unvaccinated sons reported moderate levels of willingness to get their sons free
HPV vaccine (mean=3.37, SD=1.21, possible range 1–5), with 43% definitely or probably
willing to vaccinate. In multivariate analyses, parents were more willing to get their sons
free HPV vaccine if they had more liberal political views (β=0.08), perceived higher
likelihood of their sons getting HPV-related disease (β=0.07), had daughters who had
received HPV vaccine (β=0.10), or were more comfortable talking with their sons about new
vaccines (β=0.11) (Table 2). Parents were also more willing to vaccinate if they reported
higher levels of perceived HPV vaccine effectiveness (β=0.20) or anticipated regret if they
did not get their sons HPV vaccine and they later became infected (β=0.32). Parents were
less willing to vaccinate if they perceived more potential harms of HPV vaccine (β=−0.12)
or reported higher levels of anticipated regret if their sons got vaccinated and fainted (β=
−0.14).
3.4. Sons’ Willingness to Get HPV Vaccine
Among unvaccinated sons who completed surveys, most had never heard of HPV before
their surveys (75%), with fewer being aware and having low knowledge (10%) or high
knowledge (16%) about HPV (Table 3). Similar to parents, sons perceived low likelihood of
getting HPV-related disease. Sons were mostly comfortable talking with their parents about
new vaccines, but had talked very little with their parents about HPV vaccine and reported
low levels of perceived knowledge about the vaccine. Sons indicated moderate levels of peer
acceptance of HPV vaccine and potential embarrassment about getting vaccinated. They
reported fairly high levels of anticipated regret if they did not get vaccinated and later
developed an HPV infection and if they did get vaccinated and fainted.
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Unvaccinated sons were moderately willing to get HPV vaccine (mean=2.98, SD=1.13,
possible range 1-5). Many sons were not sure about vaccination (44%) and 29% were
definitely or probably willing to get vaccinated. In multivariate analyses, sons were more
willing to get HPV vaccine if they reported higher levels of perceived likelihood of getting
HPV-related disease (β=0.16), peer acceptance of HPV vaccination (β=0.39), or anticipated
regret if they did not get vaccinated and later developed an HPV infection (β=0.22) (Table
3). Sons were also more willing to get vaccinated if they had sisters who had received HPV
vaccine (β=0.11). Sons who indicated higher levels of anticipated regret if they got
vaccinated and fainted were less willing to get HPV vaccine (β=−0.26).
3.5. Concordance Between Parents’ and Sons’ Willingness to Get HPV Vaccine
Sons’ willingness to get vaccinated was positively correlated with their parents’ willingness
to get them free HPV vaccine (r=0.52, p<0.001). Parents and sons indicated the same level
of willingness (e.g., both said “probably willing”) in 40% (166/412) of dyads with
unvaccinated sons. In an additional 37% (152/412) of these dyads, responses provided by




Almost a year after HPV vaccine was licensed and first recommended for males [13], we
found that only 2% of adolescent males had received any doses of HPV vaccine. To our
knowledge, this represents the first estimate of HPV vaccine uptake among adolescent males
in the U.S. The observed uptake rate is noticeably lower than that among adolescent females
about a year after HPV vaccine licensure occurred for them (10%-30% in 2007) [35–38].
Vaccination rates among adolescent females have increased in subsequent years, but they
remain below 50% [39] and much lower than other countries [40,41].
HPV vaccination rates may be lower among males within the first year after vaccine
licensure compared to females for several reasons. First, the ACIP recommends HPV
vaccine be administered routinely to all females aged 11–12 years (with catch-up
vaccination for females ages 13–26) [42], which is a stronger recommendation than the
current permissive recommendation provided for males [13]. This weaker recommendation
could be affecting healthcare providers’ and parents’ interest in vaccinating adolescent
males, as well as coverage of HPV vaccine for males by private health insurance plans [15].
Second, most parents and sons are still in the early stages of adoption of HPV vaccine for
males, with over 90% of parents and sons either unaware or unengaged. In comparison,
female college students were in much later stages of adoption (e.g., over 85% had heard of
HPV vaccine) within the first year after vaccine licensure for females [43]. Substantial
media coverage about HPV vaccine for females before and soon after vaccine licensure [44–
46] likely advanced females through the early stages of adoption, whereas media coverage
about HPV vaccine for males has been much less. Lastly, HPV vaccine for males was not
approved for cancer prevention until recently [17], which is important since framing HPV
vaccine as preventing cancer increases men’s willingness to receive the vaccine [47].
Education programs for parents and adolescent males are needed to increase their awareness
and knowledge about HPV vaccine and allow them to make informed vaccination decisions.
Perceived peer acceptance of HPV vaccine was the strongest correlate of vaccine
acceptability among sons. Previous studies among female college students also found peers
and social norms were important to HPV vaccine acceptability and uptake [43,48]. Potential
embarrassment of getting HPV vaccine was not, however, associated with sons’ vaccine
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acceptability in multivariate analyses, suggesting that embarrassment is not a strong
potential barrier. Taken together, our results suggest that efforts to normalize HPV
vaccination among adolescents, possibly through peer-led programs, may help increase
vaccine acceptability among adolescent males.
Additional health beliefs were associated with HPV vaccine acceptability among both
parents and sons. Specifically, anticipated regret (of both vaccinating and not vaccinating)
and perceived likelihood of sons getting HPV-related disease were important correlates
among both groups. Perceived effectiveness and perceived harms of HPV vaccine were
additional correlates among parents. Our results are similar to previous HPV vaccine
acceptability studies among males (pre-vaccine licensure) [19,21,22] and females [49,50], as
well as studies examining HPV vaccine uptake among females [29,51,52]. These modifiable
health beliefs, some of which are incorporated in the Health Belief Model (HBM) [53], offer
potential targets for future interventions to increase HPV vaccine acceptability and
potentially vaccine uptake among males. Educational materials centered around HBM
constructs have been well received in promoting influenza vaccination [54]. Given the low
awareness and knowledge levels observed in this study, such educational materials may be
an important initial strategy for increasing HPV vaccine acceptability and uptake. The use of
HBM-based vaccination reminder cards have also been successful in improving vaccination
coverage for other vaccines [55] and offer an additional possibility for future HPV vaccine
intervention studies.
Doctor’s recommendation, an key determinant of HPV vaccine acceptability and uptake
among females [29,50], was not associated with parents’ acceptability in this study, though
this is likely due to so few parents having received a recommendation to get their sons HPV
vaccine. Healthcare providers are one of the main sources of HPV vaccine information for
parents [56], and they will play an increasingly important role in vaccine acceptability and
uptake as time since vaccine licensure for males passes. Future interventions targeting
healthcare providers may therefore also help increase HPV vaccine acceptability and uptake
among males. For example, physician vaccination reminder systems increase vaccination
levels [57] yet are underused by healthcare providers [58].
Parents and sons were more accepting of HPV vaccine if they had daughters (or sisters) who
had already received HPV vaccine. These results correspond with those from our past
research conducted soon after vaccine licensure [20]. It is likely that these adolescent
females getting vaccinated increased parents’ and sons’ familiarity and general acceptance
of HPV vaccine. These findings also suggest that few of the vaccinated females had negative
HPV vaccination experiences, which may have lowered parents’ and sons’ vaccine
acceptability. Interestingly, parents’ and sons’ vaccine acceptability was not correlated with
demographic characteristics, including son’s age. This differs from studies among females,
where HPV vaccine acceptability and uptake have tended to be lower for younger ages
[35,50,59,60].
4.2. Strengths and Limitations
Our study had many strengths including the use of a national sample, collecting dyadic data
on parents and their adolescent sons, refining our surveys extensively through cognitive
testing and pretesting, and examining a wide range of potential correlates of vaccine
acceptability. Most participants were non-Hispanic white and of fairly high socioeconomic
status, though the online panel is very similar to the U.S. population on many demographic
features [61]. Panel members also regularly complete surveys, some of which may be
health-related, and this could potentially affect their responses. Our estimate of HPV vaccine
uptake was based on self-reported data, and willingness levels may overstate future
vaccination behavior since intent does not always lead to behavior [51]. We were not able to
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identify correlates of vaccine uptake since so few sons had received any doses of HPV
vaccine. Some scales did not have high levels of internal consistency, though this could be
partly due to most scales containing only a few items.
4.3. Conclusions
In this first examination of HPV vaccine uptake among adolescent males, only 2% had
received any doses of HPV vaccine nearly a year after the vaccine was licensed and first
recommended for males. Parents and sons reported moderate levels of vaccine acceptability,
and the identified correlates underscore potentially important factors affecting their HPV
vaccination decisions. Future interventions are needed to increase HPV vaccine acceptability
and uptake among adolescent males.
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Table 1




 Female 294 (54)
 Male 253 (46)
Age (Years)
 <45 332 (61)
 ≥45 215 (39)
Race / Ethnicity
 White, Non-Hispanic 366 (67)
 African American, Non-Hispanic 69 (13)
 Hispanic 83 (15)
 Other 29 (5)
Marital Status
 Divorced, Widowed, Separated, Never Married 101 (18)
 Married or Living with Partner 446 (82)
Education
 High School Degree or Less 242 (44)
 Some College or More 305 (56)
Born-Again Christian
 No 363 (66)
 Yes 184 (34)
Importance of Religion, mean (SD)a 3.60 (1.35)
Political Affiliation, mean (SD)b 2.62 (0.98)
Son Characteristicsc
Age (Years)
 11–12 128 (30)
 13–15 158 (38)
 16–17 135 (32)
Race / Ethnicity
 White, Non-Hispanic 257 (61)
 African American, Non-Hispanic 52 (12)
 Hispanic 68 (16)
 Other 44 (11)
Son Has Seen Regular Healthcare Provider in Last Year
 No 95 (23)
 Yes 326 (77)
Household Characteristics
Household Income
 <$60,000 279 (51)
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n (%)
 ≥$60,000 268 (49)
Urbanicity
 Rural 94 (17)
 Urban 453 (83)
Region of Residence
 Northeast 114 (21)
 Midwest 134 (24)
 South 188 (34)
 West 111 (20)
a
5-point response scale ranging from “not at all important” to “very important” (coded 1–5).
b
5-point response scale ranging from “very conservative” to “very liberal” (coded 1–5).
c
Data collected during parent survey, but we report data only for those sons who completed their own surveys. Sons who completed surveys were
similar to non-completers on these characteristics (all p>0.05).
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